{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T22:23:03Z","timestamp":1793312583217,"version":"4.5.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T00:00:00Z","timestamp":1750809600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T00:00:00Z","timestamp":1750809600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000065","name":"U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["K08 NS114106"],"award-info":[{"award-number":["K08 NS114106"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["UH3 NS094355"],"award-info":[{"award-number":["UH3 NS094355"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Children's Hospital of Philadelphia Research Institute"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-025-60497-8","type":"journal-article","created":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T05:02:41Z","timestamp":1750827761000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["AAV-based delivery of RNAi targeting ataxin-2 improves survival and pathology in TDP-43 mice"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6202-3900","authenticated-orcid":false,"given":"Defne A.","family":"Amado","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley B.","family":"Robbins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine R.","family":"Whiteman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia R.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2750-9037","authenticated-orcid":false,"given":"Guillem","family":"Chillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonghong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-0618-2113","authenticated-orcid":false,"given":"Joshua A.","family":"Fuller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-1240-1002","authenticated-orcid":false,"given":"Nicholas A.","family":"Patty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandar","family":"Izda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Congsheng","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shareen","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3797-4987","authenticated-orcid":false,"given":"Abigail I.","family":"Dichter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esteban O.","family":"Mazzoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex Mas","family":"Monteys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3715-6290","authenticated-orcid":false,"given":"Beverly L.","family":"Davidson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,25]]},"reference":[{"key":"60497_CR1","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/S1474-4422(17)30401-5","volume":"17","author":"R Chia","year":"2018","unstructured":"Chia, R., Chi\u00f2, A. & Traynor, B. J. Novel genes associated with amyotrophic lateral sclerosis: diagnostic and clinical implications. Lancet Neurol. 17, 94\u2013102 (2018).","journal-title":"Lancet Neurol."},{"key":"60497_CR2","doi-asserted-by":"publisher","unstructured":"Y. Yun, Y. Ha, CRISPR\/Cas9-Mediated Gene Correction to Understand ALS. Int. J. Mol. Sci. 21, https:\/\/doi.org\/10.3390\/ijms21113801 (2020).","DOI":"10.3390\/ijms21113801"},{"key":"60497_CR3","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1523\/JNEUROSCI.4988-09.2010","volume":"30","author":"SJ Barmada","year":"2010","unstructured":"Barmada, S. J. et al. Cytoplasmic mislocalization of TDP-43 is toxic to neurons and enhanced by a mutation associated with familial amyotrophic lateral sclerosis. J. Neurosci. 30, 639\u2013649 (2010).","journal-title":"J. Neurosci."},{"key":"60497_CR4","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/s00401-015-1460-x","volume":"130","author":"AK Walker","year":"2015","unstructured":"Walker, A. K. et al. Functional recovery in new mouse models of ALS\/FTLD after clearance of pathological cytoplasmic TDP-43. Acta Neuropathol. 130, 643\u2013660 (2015).","journal-title":"Acta Neuropathol."},{"key":"60497_CR5","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1038\/s41586-022-04424-7","volume":"603","author":"XR Ma","year":"2022","unstructured":"Ma, X. R. et al. TDP-43 represses cryptic exon inclusion in the FTD-ALS gene UNC13A. Nature 603, 124\u2013130 (2022).","journal-title":"Nature"},{"key":"60497_CR6","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1038\/s41593-018-0293-z","volume":"22","author":"Z Melamed","year":"2019","unstructured":"Melamed, Z. et al. Premature polyadenylation-mediated loss of stathmin-2 is a hallmark of TDP-43-dependent neurodegeneration. Nat. Neurosci. 22, 180\u2013190 (2019).","journal-title":"Nat. Neurosci."},{"key":"60497_CR7","doi-asserted-by":"publisher","first-page":"19437","DOI":"10.1074\/jbc.M116.737726","volume":"291","author":"R Cascella","year":"2016","unstructured":"Cascella, R. et al. Quantification of the Relative Contributions of Loss-of-function and Gain-of-function Mechanisms in TAR DNA-binding Protein 43 (TDP-43) Proteinopathies. J. Biol. Chem. 291, 19437\u201319448 (2016).","journal-title":"J. Biol. Chem."},{"key":"60497_CR8","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1038\/nature22038","volume":"544","author":"LA Becker","year":"2017","unstructured":"Becker, L. A. et al. Therapeutic reduction of ataxin-2 extends lifespan and reduces pathology in TDP-43 mice. Nature 544, 367\u2013371 (2017).","journal-title":"Nature"},{"key":"60497_CR9","unstructured":"Ravits, J. Biogen updates. Oral presentation, ENCALS meeting 2024, Stockholm, Sweden (2024)."},{"key":"60497_CR10","doi-asserted-by":"publisher","first-page":"3858","DOI":"10.1073\/pnas.0912417107","volume":"107","author":"H Wils","year":"2010","unstructured":"Wils, H. et al. TDP-43 transgenic mice develop spastic paralysis and neuronal inclusions characteristic of ALS and frontotemporal lobar degeneration. Proc. Natl. Acad. Sci. USA 107, 3858\u20133863 (2010).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"60497_CR11","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.ymthe.2022.12.018","volume":"31","author":"PT Ranum","year":"2023","unstructured":"Ranum, P. T. et al. Cochlear transduction via cerebrospinal fluid delivery of AAV in non-human primates. Mol. Ther. 31, 609\u2013612 (2023).","journal-title":"Mol. Ther."},{"key":"60497_CR12","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1007\/s12035-013-8427-5","volume":"48","author":"J Janssens","year":"2013","unstructured":"Janssens, J. et al. Overexpression of ALS-associated p.M337V human TDP-43 in mice worsens disease features compared to wild-type human TDP-43 mice. Mol. Neurobiol. 48, 22\u201335 (2013).","journal-title":"Mol. Neurobiol."},{"key":"60497_CR13","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s00401-008-0477-9","volume":"117","author":"M Neumann","year":"2009","unstructured":"Neumann, M. et al. Phosphorylation of S409\/410 of TDP-43 is a consistent feature in all sporadic and familial forms of TDP-43 proteinopathies. Acta Neuropathol. 117, 137\u2013149 (2009).","journal-title":"Acta Neuropathol."},{"key":"60497_CR14","doi-asserted-by":"publisher","DOI":"10.1212\/NXG.0000000000000476","volume":"6","author":"M Kazamel","year":"2020","unstructured":"Kazamel, M. et al. Fibulin-5 mutation featuring Charcot-Marie-Tooth disease, joint hyperlaxity, and scoliosis. Neurol. Genet 6, e476 (2020).","journal-title":"Neurol. Genet"},{"key":"60497_CR15","doi-asserted-by":"publisher","first-page":"e0302280","DOI":"10.1371\/journal.pone.0302280","volume":"19","author":"R Lumi","year":"2024","unstructured":"Lumi, R. et al. Small peptide CSF fingerprint of amyotrophic lateral sclerosis. PLoS One 19, e0302280 (2024).","journal-title":"PLoS One"},{"key":"60497_CR16","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.nbd.2014.12.002","volume":"74","author":"E Aronica","year":"2015","unstructured":"Aronica, E. et al. Molecular classification of amyotrophic lateral sclerosis by unsupervised clustering of gene expression in motor cortex. Neurobiol. Dis. 74, 359\u2013376 (2015).","journal-title":"Neurobiol. Dis."},{"key":"60497_CR17","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1038\/s42255-023-00838-3","volume":"5","author":"Y-H Tai","year":"2023","unstructured":"Tai, Y.-H. et al. Targeting the TCA cycle can ameliorate widespread axonal energy deficiency in neuroinflammatory lesions. Nat. Metab. 5, 1364\u20131381 (2023).","journal-title":"Nat. Metab."},{"key":"60497_CR18","doi-asserted-by":"publisher","first-page":"2882","DOI":"10.1093\/hmg\/ddx170","volume":"26","author":"MA Farg","year":"2017","unstructured":"Farg, M. A., Konopka, A., Soo, K. Y., Ito, D. & Atkin, J. D. The DNA damage response (DDR) is induced by the C9orf72 repeat expansion in amyotrophic lateral sclerosis. Hum. Mol. Genet. 26, 2882\u20132896 (2017).","journal-title":"Hum. Mol. Genet."},{"key":"60497_CR19","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1021\/acschemneuro.7b00297","volume":"9","author":"K Chen","year":"2018","unstructured":"Chen, K. et al. Neurodegenerative disease proteinopathies are connected to distinct histone post-translational modification landscapes. ACS Chem. Neurosci. 9, 838\u2013848 (2018).","journal-title":"ACS Chem. Neurosci."},{"key":"60497_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e16910","volume":"9","author":"MA Rather","year":"2023","unstructured":"Rather, M. A. et al. TRP channels: role in neurodegenerative diseases and therapeutic targets. Heliyon 9, e16910 (2023).","journal-title":"Heliyon"},{"key":"60497_CR21","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.neuroscience.2010.10.040","volume":"172","author":"C Moreau","year":"2011","unstructured":"Moreau, C. et al. Deregulation of the hypoxia inducible factor-1\u03b1 pathway in monocytes from sporadic amyotrophic lateral sclerosis patients. Neuroscience 172, 110\u2013117 (2011).","journal-title":"Neuroscience"},{"key":"60497_CR22","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1111\/j.1600-0404.1989.tb03735.x","volume":"79","author":"L Werdelin","year":"1989","unstructured":"Werdelin, L. et al. Neuropeptides and neural cell adhesion molecule (NCAM) in CSF from patients with ALS. Acta Neurol. Scand. 79, 177\u2013181 (1989).","journal-title":"Acta Neurol. Scand."},{"key":"60497_CR23","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1111\/cns.12204","volume":"20","author":"A Gianforcaro","year":"2014","unstructured":"Gianforcaro, A. & Hamadeh, M. J. Vitamin D as a potential therapy in amyotrophic lateral sclerosis. CNS Neurosci. Ther. 20, 101\u2013111 (2014).","journal-title":"CNS Neurosci. Ther."},{"key":"60497_CR24","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1038\/ng.2434","volume":"44","author":"M Armakola","year":"2012","unstructured":"Armakola, M. et al. Inhibition of RNA lariat debranching enzyme suppresses TDP-43 toxicity in ALS disease models. Nat. Genet 44, 1302\u20131309 (2012).","journal-title":"Nat. Genet"},{"key":"60497_CR25","doi-asserted-by":"crossref","unstructured":"Hansen, S. T., Meera, P., Otis, T. S. & Pulst, S. M. Changes in Purkinje cell firing and gene expression precede behavioral pathology in a mouse model of SCA2. Hum. Mol. Genet. 22, 271\u2013283 (2013).","DOI":"10.1093\/hmg\/dds427"},{"key":"60497_CR26","doi-asserted-by":"publisher","unstructured":"D. An, et al. Stem cell-derived cranial and spinal motor neurons reveal proteostatic differences between ALS resistant and sensitive motor neurons. Elife 8, https:\/\/doi.org\/10.7554\/eLife.44423 (2019).","DOI":"10.7554\/eLife.44423"},{"key":"60497_CR27","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.omtn.2019.02.001","volume":"16","author":"R Martier","year":"2019","unstructured":"Martier, R. et al. Targeting RNA-Mediated Toxicity in C9orf72 ALS and\/or FTD by RNAi-Based Gene Therapy. Mol. Ther. Nucleic Acids 16, 26\u201337 (2019).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"60497_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-42147-z","volume":"14","author":"MA Zeballos C","year":"2023","unstructured":"Zeballos C, M. A. et al. Mitigating a TDP-43 proteinopathy by targeting ataxin-2 using RNA-targeting CRISPR effector proteins. Nat. Commun. 14, 6492 (2023).","journal-title":"Nat. Commun."},{"key":"60497_CR29","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1038\/s41593-021-00827-3","volume":"24","author":"M Van Alstyne","year":"2021","unstructured":"Van Alstyne, M. et al. Gain of toxic function by long-term AAV9-mediated SMN overexpression in the sensorimotor circuit. Nat. Neurosci. 24, 930\u2013940 (2021).","journal-title":"Nat. Neurosci."},{"key":"60497_CR30","unstructured":"uniQure announces positive interim data update demonstrating slowing of disease progression in phase I\/II trials of AMT-130 for Huntington\u2019s Disease. Press Release https:\/\/uniqure.gcs-web.com\/node\/11781\/pdf (2024)."},{"key":"60497_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2023.102057","volume":"34","author":"SK Chen","year":"2023","unstructured":"Chen, S. K. et al. Efficacy and safety of a SOD1-targeting artificial miRNA delivered by AAV9 in mice are impacted by miRNA scaffold selection. Mol. Ther. Nucleic Acids 34, 102057 (2023).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"60497_CR32","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1261\/rna.1062908","volume":"14","author":"RL Boudreau","year":"2008","unstructured":"Boudreau, R. L., Monteys, A. M. & Davidson, B. L. Minimizing variables among hairpin-based RNAi vectors reveals the potency of shRNAs. RNA 14, 1834\u20131844 (2008).","journal-title":"RNA"},{"key":"60497_CR33","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s40035-022-00322-0","volume":"11","author":"I Agrawal","year":"2022","unstructured":"Agrawal, I., Lim, Y. S., Ng, S.-Y. & Ling, S.-C. Deciphering lipid dysregulation in ALS: from mechanisms to translational medicine. Transl. Neurodegener. 11, 48 (2022).","journal-title":"Transl. Neurodegener."},{"key":"60497_CR34","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.semcdb.2020.08.012","volume":"112","author":"TJ Tracey","year":"2021","unstructured":"Tracey, T. J., Kirk, S. E., Steyn, F. J. & Ngo, S. T. The role of lipids in the central nervous system and their pathological implications in amyotrophic lateral sclerosis. Semin Cell Dev. Biol. 112, 69\u201381 (2021).","journal-title":"Semin Cell Dev. Biol."},{"key":"60497_CR35","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1136\/jnnp-2020-323611","volume":"91","author":"SA Goutman","year":"2020","unstructured":"Goutman, S. A. et al. Untargeted metabolomics yields insight into ALS disease mechanisms. J. Neurol. Neurosurg. Psychiatry 91, 1329\u20131338 (2020).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"60497_CR36","doi-asserted-by":"publisher","first-page":"e0198116","DOI":"10.1371\/journal.pone.0198116","volume":"13","author":"H Blasco","year":"2018","unstructured":"Blasco, H. et al. A pharmaco-metabolomics approach in a clinical trial of ALS: identification of predictive markers of progression. PLoS One 13, e0198116 (2018).","journal-title":"PLoS One"},{"key":"60497_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-17389-9","volume":"7","author":"H Blasco","year":"2017","unstructured":"Blasco, H. et al. Lipidomics reveals cerebrospinal-fluid signatures of ALS. Sci. Rep. 7, 17652 (2017).","journal-title":"Sci. Rep."},{"key":"60497_CR38","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1093\/hmg\/ddn035","volume":"17","author":"I Lastres-Becker","year":"2008","unstructured":"Lastres-Becker, I. et al. Insulin receptor and lipid metabolism pathology in ataxin-2 knock-out mice. Hum. Mol. Genet 17, 1465\u20131481 (2008).","journal-title":"Hum. Mol. Genet"},{"key":"60497_CR39","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1212\/01.wnl.0000285080.70324.27","volume":"70","author":"L Dupuis","year":"2008","unstructured":"Dupuis, L. et al. Dyslipidemia is a protective factor in amyotrophic lateral sclerosis. Neurology 70, 1004\u20131009 (2008).","journal-title":"Neurology"},{"key":"60497_CR40","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1074\/mcp.M115.056770","volume":"15","author":"D Meierhofer","year":"2016","unstructured":"Meierhofer, D., Halbach, M., \u015een, N. E., Gispert, S. & Auburger, G. Ataxin-2 (Atxn2)-knock-out mice show branched chain amino acids and fatty acids pathway alterations. Mol. Cell Proteom. 15, 1728\u20131739 (2016).","journal-title":"Mol. Cell Proteom."},{"key":"60497_CR41","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1080\/01616412.2016.1250458","volume":"39","author":"G Deng","year":"2017","unstructured":"Deng, G. & Jin, L. The effects of vasoactive intestinal peptide in neurodegenerative disorders. Neurol. Res 39, 65\u201372 (2017).","journal-title":"Neurol. Res"},{"key":"60497_CR42","doi-asserted-by":"publisher","unstructured":"Shim, J. W. & Madsen, J. R. VEGF signaling in neurological disorders. Int. J. Mol. Sci. 19, https:\/\/doi.org\/10.3390\/ijms19010275 (2018).","DOI":"10.3390\/ijms19010275"},{"key":"60497_CR43","doi-asserted-by":"publisher","DOI":"10.1186\/1742-2094-8-47","volume":"8","author":"PK Gupta","year":"2011","unstructured":"Gupta, P. K., Prabhakar, S., Sharma, S. & Anand, A. Vascular endothelial growth factor-A (VEGF-A) and chemokine ligand-2 (CCL2) in amyotrophic lateral sclerosis (ALS) patients. J. Neuroinflammation 8, 47 (2011).","journal-title":"J. Neuroinflammation"},{"key":"60497_CR44","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.bbrc.2007.09.088","volume":"363","author":"C Zheng","year":"2007","unstructured":"Zheng, C. et al. VEGF reduces astrogliosis and preserves neuromuscular junctions in ALS transgenic mice. Biochem. Biophys. Res. Commun. 363, 989\u2013993 (2007).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"60497_CR45","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/ng1211","volume":"34","author":"D Lambrechts","year":"2003","unstructured":"Lambrechts, D. et al. VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat. Genet. 34, 383\u2013394 (2003).","journal-title":"Nat. Genet."},{"key":"60497_CR46","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.expneurol.2014.09.022","volume":"263","author":"S Goursaud","year":"2015","unstructured":"Goursaud, S. et al. The anti-inflammatory peptide stearyl-norleucine-VIP delays disease onset and extends survival in a rat model of inherited amyotrophic lateral sclerosis. Exp. Neurol. 263, 91\u2013101 (2015).","journal-title":"Exp. Neurol."},{"key":"60497_CR47","doi-asserted-by":"publisher","first-page":"2627","DOI":"10.1007\/s00018-010-0575-4","volume":"68","author":"A Augstein","year":"2011","unstructured":"Augstein, A., Poitz, D. M., Braun-Dullaeus, R. C., Strasser, R. H. & Schmeisser, A. Cell-specific and hypoxia-dependent regulation of human HIF-3\u03b1: inhibition of the expression of HIF target genes in vascular cells. Cell Mol. Life Sci. 68, 2627\u20132642 (2011).","journal-title":"Cell Mol. Life Sci."},{"key":"60497_CR48","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1002\/ana.20379","volume":"57","author":"Y-M Jiang","year":"2005","unstructured":"Jiang, Y.-M. et al. Gene expression profile of spinal motor neurons in sporadic amyotrophic lateral sclerosis. Ann. Neurol. 57, 236\u2013251 (2005).","journal-title":"Ann. Neurol."},{"key":"60497_CR49","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1097\/nen.0b013e318093ece3","volume":"66","author":"Y-M Jiang","year":"2007","unstructured":"Jiang, Y.-M. et al. Gene expressions specifically detected in motor neurons (dynactin 1, early growth response 3, acetyl-CoA transporter, death receptor 5, and cyclin C) differentially correlate to pathologic markers in sporadic amyotrophic lateral sclerosis. J. Neuropathol. Exp. Neurol. 66, 617\u2013627 (2007).","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"60497_CR50","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.mcn.2007.02.004","volume":"35","author":"L Li","year":"2007","unstructured":"Li, L. et al. Egr3, a synaptic activity regulated transcription factor that is essential for learning and memory. Mol. Cell Neurosci. 35, 76\u201388 (2007).","journal-title":"Mol. Cell Neurosci."},{"key":"60497_CR51","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-022-02069-8","volume":"12","author":"KK Marballi","year":"2022","unstructured":"Marballi, K. K. et al. Identification of activity-induced Egr3-dependent genes reveals genes associated with DNA damage response and schizophrenia. Transl. Psychiatry 12, 320 (2022).","journal-title":"Transl. Psychiatry"},{"key":"60497_CR52","doi-asserted-by":"publisher","first-page":"e9","DOI":"10.1093\/nar\/gks797","volume":"41","author":"RL Boudreau","year":"2013","unstructured":"Boudreau, R. L. et al. siSPOTR: a tool for designing highly specific and potent siRNAs for human and mouse. Nucleic Acids Res. 41, e9 (2013).","journal-title":"Nucleic Acids Res."},{"key":"60497_CR53","doi-asserted-by":"publisher","first-page":"13315","DOI":"10.1093\/nar\/gku979","volume":"42","author":"AM Monteys","year":"2014","unstructured":"Monteys, A. M. et al. Single nucleotide seed modification restores in vivo tolerability of a toxic artificial miRNA sequence in the mouse brain. Nucleic Acids Res. 42, 13315\u201313327 (2014).","journal-title":"Nucleic Acids Res."},{"key":"60497_CR54","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1002\/ana.24789","volume":"80","author":"MS Keiser","year":"2016","unstructured":"Keiser, M. S., Monteys, A. M., Corbau, R., Gonzalez-Alegre, P. & Davidson, B. L. RNAi prevents and reverses phenotypes induced by mutant human ataxin-1. Ann. Neurol. 80, 754\u2013765 (2016).","journal-title":"Ann. Neurol."},{"key":"60497_CR55","doi-asserted-by":"publisher","unstructured":"S. J. Guyenet, et al. A simple composite phenotype scoring system for evaluating mouse models of cerebellar ataxia. J. Vis. Exp. https:\/\/doi.org\/10.3791\/1787 (2010).","DOI":"10.3791\/1787"},{"key":"60497_CR56","doi-asserted-by":"crossref","unstructured":"Stringer, C. & Pachitariu, M. Cellpose3: one-click image restoration for improved cellular segmentation. Nat. Methods 22, 592\u2013599 (2025).","DOI":"10.1038\/s41592-025-02595-5"},{"key":"60497_CR57","doi-asserted-by":"publisher","unstructured":"Robbins A. B., AAV-based delivery of RNAi targeting ataxin-2 improves survival and pathology in TDP-43 mice, GitHub repository https:\/\/doi.org\/10.5281\/zenodo.15427428 (2025).","DOI":"10.5281\/zenodo.15427428"}],"updated-by":[{"DOI":"10.1038\/s41467-025-65424-5","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:00:00Z","timestamp":1761177600000}}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-60497-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-60497-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-60497-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T07:04:50Z","timestamp":1761289490000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-60497-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,25]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["60497"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-60497-8","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,25]]},"assertion":[{"value":"12 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2025","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41467-025-65424-5","URL":"https:\/\/doi.org\/10.1038\/s41467-025-65424-5","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Y.H.C. and B.L.D. are founders of Latus Bio and have stock options. B.L.D. has sponsored research or serves an advisory role for Carbon Bio, Resilience, Roche, and Latus Bio. The other authors declare they have no competing interests. Two patents have been submitted by the Children\u2019s Hospital of Philadelphia: PCT\/US2023\/071845, \u2018MIRNAS Targeting ATXN2 for the Treatment of ALS and SCA2,\u2019 D.A.A., A.M.M., and B.L.D., covering the RNAi sequences used in this manuscript; and PCT\/US2020\/061464, \u2018Adeno-Associated Viral Vector Variants,\u2019 Y.C. and B.L.D., covering the AAV capsid used in this manuscript.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5334"}}